PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Publications
Contact Us
Log In
You need to enable JavaScript to run this app page.
Pancreas
BCM-PDAC-29
Model Details
Patient
PDX Model
Histology
Metastasis
Patient Treatment
Patient Information for Model: BCM-PDAC-29
Contact Model Developer
Model Contact
Model: BCM-PDAC-29
Model Contact: Qizhi Cathy Yao
Institution: BCM Pancreas PDX Program
Email:
qizhiyao@bcm.edu
Patient Information
Clinical Timeline
Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection
Model Information for Model: BCM-PDAC-29
Model Details - Initial Implantation of Patient Tissue
Mutations (Cancer Gene Census List)
Show/Hide Columns
Total mutations showing: 59
F
P
1
2
3
4
N
E
Rows Per Page
10
15
25
50
Download
Gene
Filter by Gene
Chr
Filter by Chr
Start
End
Ref
Alt
cDNA Change
Codon Change
Protein Change
TVAF
Gene Mutation Freq.
Site Mutation Freq.
Most Severe Effect
All Effects
Mutation Impact
Transcript ID
ClinVar Clinical Significance
COSMIC ID
gnomAD Non-Cancer AF
dbSNP ID
Gene Mutation Freq.
Site Mutation Freq.
Transcript ID
ClinVar Clinical Significance
COSMIC ID
dbSNP ID
AFF3
chr2
99593872
99593873
CG
C
c.1863del
gcC/gc
p.D623Tfs*48
0.466
8
4
Frameshift Mutation
Frameshift Mutation
HIGH
ENST00000409579.5
COSV57841232
rs201754690
8
4
ENST00000409579.5
COSV57841232
rs201754690
AKAP9
chr7
92022864
92022864
A
AAAC
c.4004_4006dup
aaa/aAACaa
p.K1335_L1336insQ
0.774
15
13
In-frame Insertion
In-frame Insertion
MODERATE
ENST00000356239.8
COSV62337888
rs10644111
15
13
ENST00000356239.8
COSV62337888
rs10644111
AR
chrX
67545316
67545316
T
TGCAGCAGCA
c.231_239dup
ctg/ctGCAGCAGCAg
p.Q78_Q80dup
0.72
17
3
In-frame Insertion
In-frame Insertion
MODERATE
ENST00000374690.9
COSV105309998
17
3
ENST00000374690.9
COSV105309998
ARID1A
chr1
26779283
26779283
G
C
c.5385G>C
aaG/aaC
p.K1795N
0.55
12
3
Missense Variant
Missense Variant
MODERATE
ENST00000324856.13
COSV61388346
0.000025336300
rs200221564
12
3
ENST00000324856.13
COSV61388346
rs200221564
ATM
chr11
108256249
108256249
G
A
c.2159G>A
cGt/cAt
p.R720H
0.355
12
3
Missense Variant
Missense Variant
MODERATE
ENST00000278616.8
Uncertain_significance
COSV99592647
0.000050739500
rs55830714
12
3
ENST00000278616.8
Uncertain_significance
COSV99592647
rs55830714
ATRX
chrX
77682471
77682471
C
G
c.2785G>C
Gag/Cag
p.E929Q
0.999
20
20
Missense Variant
Missense Variant
MODERATE
ENST00000373344.10
Benign
rs3088074
20
20
ENST00000373344.10
Benign
rs3088074
AXIN1
chr16
288189
288189
C
T
c.2522G>A
cGa/cAa
p.R841Q
0.514
3
3
Missense Variant
Missense Variant
MODERATE
ENST00000262320.8
Benign
COSV51989077
0.008448000000
rs34015754
3
3
ENST00000262320.8
Benign
COSV51989077
rs34015754
BCR
chr22
23253862
23253862
G
A
c.1343G>A
cGg/cAg
p.R448Q
0.503
7
3
Missense Variant
Missense Variant
MODERATE
ENST00000305877.13
0.000093353200
rs370367734
7
3
ENST00000305877.13
rs370367734
CIITA
chr16
10909070
10909070
A
G
c.2702A>G
cAg/cGg
p.Q901R
0.981
24
24
Missense Variant
Missense Variant
MODERATE
ENST00000618327.4
Benign
0.983235000000
rs7197779
24
24
ENST00000618327.4
Benign
rs7197779
DCC
chr18
52340854
52340854
T
C
c.67T>C
Ttc/Ctc
p.F23L
0.9
6
5
Missense Variant
Missense Variant
MODERATE
ENST00000442544.7
Benign
0.985567000000
rs9951523
6
5
ENST00000442544.7
Benign
rs9951523
DDB2
chr11
47238177
47238177
G
A
c.1228G>A
Gca/Aca
p.A410T
0.205
5
5
Missense Variant
Missense Variant
MODERATE
ENST00000256996.9
Conflicting_interpretations_of_pathogenicity
COSV104563756
0.002523310000
rs143049891
5
5
ENST00000256996.9
Conflicting_interpretations_of_pathogenicity
COSV104563756
rs143049891
EPHA3
chr3
89340984
89340984
T
C
c.883T>C
Tct/Cct
p.S295P
0.264
3
3
Missense Variant
Missense Variant
MODERATE
ENST00000336596.7
3
3
ENST00000336596.7
ERCC2
chr19
45351661
45351661
T
G
c.2251A>C
Aag/Cag
p.K751Q
0.978
16
15
Missense Variant
Missense Variant
MODERATE
ENST00000391945.10
Benign/Likely_benign
COSV67266431
0.322955000000
rs13181
16
15
ENST00000391945.10
Benign/Likely_benign
COSV67266431
rs13181
ERCC4
chr16
13920182
13920182
C
A
c.17C>A
cCg/cAg
p.P6Q
0.578
7
3
Missense Variant
Missense Variant
MODERATE
ENST00000311895.8
7
3
ENST00000311895.8
EZH2
chr7
148828812
148828812
C
G
c.553G>C
Gac/Cac
p.D185H
0.974
11
9
Missense Variant
Missense Variant
MODERATE
ENST00000320356.7
Benign
COSV57449162
0.078149200000
rs2302427
11
9
ENST00000320356.7
Benign
COSV57449162
rs2302427
Total mutations showing: 59
F
P
1
2
3
4
N
E
Rows Per Page
10
15
25
50
Download
CNV
Histology Information for Model: BCM-PDAC-29
There are no histology images for this model.
Metastasis Information for Model: BCM-PDAC-29
Patient
PDX
Liver
Local recurrence
Lung
Rectum
lymph node
Patient Treatment Information for Model: BCM-PDAC-29
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
Reason Stopped
10
Gemcitabine/capecitabine
Adjuvant
65.61
65.92
113 days
Complete Response (CR); "No evidence of disease"
Completed regimen
15
chemo/radiation
Adjuvant
66.03
66.13
36 days
Complete Response (CR); "No evidence of disease"
Completed regimen
20
Gemcitabine/Abraxane
Adjuvant
67.17
67.23
22 days
Stopped due to side effects
25
Gemcitabine
Adjuvant
67.34
67.38
15 days
Progressive Disease (PD)
Stopped due to disease progression
30
Gemcitabine/Capecitabine
Adjuvant
67.44
67.67
84 days
Unknown
Completed regimen
Please wait...
Gene
Chr
Start
End
Ref
Alt
cDNA Change
Codon Change
Protein Change
TVAF
Gene Mutation Freq.
Site Mutation Freq.
Most Severe Effect
All Effects
Mutation Impact
Transcript ID
ClinVar Clinical Significance
COSMIC ID
gnomAD Non-Cancer AF
dbSNP ID
The number of models in this collection with mutations in the listed gene;
may include models that are not publicly available for distribution.
The number of models in this collection with mutations at the listed site;
may include models that are not publicly available for distribution.